Primarily, the predetermined affinity that receptors and ligands have for multiple binding partners may prove advantageous, as seen in the case of the TriPRIL CAR T cells that dually target two receptors commonly co-expressed in multiple myeloma, B-cell maturation antigen (BCMA) and transmembrane activator and calcium-modulator and cyclophilin ligand (TACI) [57]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.